

2023 #8

February 24, 2023

INSIDE:

ABC Blood Advocacy
Week Begins April 24th .2
RESEARCH IN BRIEF3
INFECTIOUS DISEASES
UPDATE.....4
PEOPLE.....6
MEMBER NEWS.....6
CALENDAR.....7
POSITIONS.....8

Jed Gorlin, MD Named ABC Chief Medical Officer



America's Blood Centers (ABC) announced this week that Jed Gorlin, MD, MBA will become chief medical officer (CMO) effective March 1st. Dr. Gorlin succeeds Rita Reik, MD, FCAP who is stepping down as CMO at the end of February, a position she has held since May 2019. In this role, Dr. Gorlin will lead ABC's scientific and medical activities while continuing to position ABC as national leader in shaping the future of the blood community and transfusion medicine.

Dr. Gorlin is the vice president of Medical and Quality Affairs for New York Blood Centers Enterprises (NYBCE), serving the NYBCE divisions of Memorial Blood Center, Nebraska Community Blood Bank, and Community Blood Center of Greater Kansas City. He also serves as the co-director of Transfusion Medicine at Hennepin County Medical Center, a level one trauma hospital in Minneapolis, Minn., Children's Hospitals and Clinics in Minneapolis and St. Paul, Minn. in addition to being the medical director of the New York Blood Center Transfusion Medicine Fellowship Program.

He received his medical degree from Yale and his Master of Business Administration from the University of Minnesota Carlson School. Dr. Gorlin also holds a Bachelor of Science degree from Stanford University. According to his bio, he trained in Pediatrics and Pediatric Hematology-Oncology at Boston Children's hospital and Dana/Farber Cancer Institute.

Dr. Gorlin has also served on the board of directors at the Association for the Advancement of Blood & Biotherapies (AABB) and the National Blood Foundation. He is the Associate Clinical Professor of laboratory medicine at University of Minnesota and is a senior editor of *Transfusion Medicine and Apheresis Science*. Throughout his career, Dr. Gorlin has authored more than 60 journal articles and a dozen chapters in various blood banking texts. He lectures to the medical laboratory scientist students at the University of Minnesota and Kansas University Medical Center.

He has also been a consultant to AABB, the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH) for blood collection capacity building projects in Rwanda, Tanzania and Central Asia including Kazakhstan and Kyrgyzstan. Dr. Gorlin has also been a consultant to the World Health Organization (WHO) for patient blood management. He was the AABB liaison for

(continued on page 2)



Jed Gorlin Named ABC CMO (continued from page 1)

obstetric hemorrhage to the American College of Obstetricians and Gynecologists, the Association of Women's Health, Obstetric and Neonatal, and the California Maternal Quality Care Collaborative. Dr. Gorlin is also chair of the AABB Transfusion Transmitted Diseases committee. He has been a recipient of the John Elliott Memorial Award (2019) and President's Award (2022) from AABB. Dr. Gorlin is a panel member of the Advisory Committee for Blood and Tissue Safety and Availability (ACBTSA), that reports to the U.S. Department of Health and Human Safety (HHS).

(Source: MCN 23-019, 2/22/23) 💧

ABC Blood Advocacy Week Begins April 24th

America's Blood Centers (ABC) is set to kick off the inaugural [Blood Advocacy Week](#) April 24th-28th. This initiative reinforces ABC's commitment to advocacy and advancing policies that assist community blood centers. This virtual event aims to bring together members of the blood community, legislators, agency decision makers, advocates, providers, patients, and more to learn about and advance ABC's advocacy efforts on behalf of member blood centers. It includes the following:



- Monday, April 24th will be dedicated to discussing the current [status](#) of the nation's blood supply and trends impacting the collection and utilization of blood;
- Tuesday, April 25th will be dedicated to promoting the awareness of FDA donor [eligibility](#) changes impacting veterans and gay and bisexual men;
- Wednesday, April 26th will be ABC's virtual "Day on Capitol Hill." [Registration](#) is now open.
- Thursday, April 27th will be dedicated to examining changes that will expand early and increased access to blood, including in [pre-hospital](#) and [hospice](#) settings;
- Friday, April 28th will be dedicated to highlighting why increased [diversity](#) – racial, ethnic, and age – is important to patient care.

Additional updates will be provided in the coming weeks. If you or your organization is interested in becoming an official [advocacy partner](#), please contact [Jeff Gohringer](#), director of Strategic Communications and National Partnerships at ABC.

ABC also encourages all member blood centers to register for the [2023 "Day on Capitol Hill"](#) on April 26th. This "virtual" day provides an opportunity for member blood centers to connect with members of Congress and their staffs to discuss the ongoing work at the blood center and the work done collectively by ABC and community blood centers to advance the ABC Advocacy Agenda. This event is a chance for individuals to let their voice be heard as ABC will arrange the virtual meetings for member blood centers with their members of Congress and provide additional resources to help inform them and their staff about the latest policies impacting the blood community. Take advantage of this opportunity to easily meet with your local Congressional leaders and build relationships. Each person from the blood center who would like to participate in the "Day on Capitol Hill" must register individually. ABC will arrange for group meetings but will need information for each person in attendance. Additional details, including the 2023 Advocacy Agenda, will be forthcoming. Please direct any questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: MCN 23-020, 2/24/23) 💧



RESEARCH IN BRIEF

Immune Globulin Usage Continues to Rise. A [study](#) in *Transfusion* “used two large population-based claims databases within the Biologics Effectiveness and Safety (BEST) network to assess changes in immune globulins (IG) utilization in the U.S. across different care settings in the past decade.” The authors “used IBM MarketScan commercial claims database and Medicare enrollment and claims data from the Centers for Medicare and Medicaid Services (CMS) [from] January 1, 2009, to December 31, 2019.” The study “evaluate[d] IG utilization [by] assess[ing] four metrics on an annual basis, including:

- [the] aggregate number of administrations (per 100,000 enrollee person-years);
- [the] number of individuals receiving at least one IG administration (per 100,000 enrollees);
- [the] average number of administrations per IG recipient; and
- [the] average IG dose per individual.”

The researchers found that the “[n]umber of administrations increased by 120 percent for the commercially insured population (from 213 to 470 per 100,000 person-years) and by 144 percent for the Medicare population (from 692 to 1,693). [The] number of individuals receiving IG increased in both the commercially insured (by 71 percent, from 24 to 42 per 100,000 enrollees) and Medicare (by 102 percent, from 89 to 179) populations. Average administrations per individual receiving IG increased by 28 percent (from 8 to 10 per year) for the commercially insured and 19 percent (from eight to nine) for Medicare enrollees. Similarly, average annual dose per recipient increased by 29 percent (from 384 to 497 g) for the commercially insured and by 34 percent (from 317 to 426 g) for Medicare enrollees.” They also noted that the “[n]umber of administrations for individuals with immunodeficiency increased from 127 to 321 administrations per 100,000 person-years (154 percent increase) among commercially insured individuals and from 365 to 1,007 administrations (176 percent increase) among Medicare beneficiaries...IG recipients with neurologic or autoimmune/connective tissue disorders had the highest annual average number of administrations per recipient and annual dose per recipient.” The study concluded that “in the U.S. population [there was] a substantial overall increase in IG use, primarily reflecting an increase in the number of individuals receiving IG.” The authors called for “[f]uture studies [to] further assess the impact of increased IG usage on patient outcomes.”

Citation: Jiao, Y., Moll, K., Dore, G.M., Tworowski, E., Zhou, C.K., Scott, D., *et al.* [Immune globulin usage trends in commercially insured and Medicare populations, 2009–2019.](#) *Transfusion.* 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood.

(continued on page 4)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



RESEARCH IN BRIEF (continued from page 3)

Gene Therapy to Treat Hemophilia B Superior to Factor IX? Investigators in the *New England Journal of Medicine* have [published](#) data from a phase III, open-label, single-dose international study that examined the “safety and efficacy” of a hemophilia B gene therapy (etranacogene dezaparvovec). They explained that individuals participating in this study were males 18 years of age or older who “have inherited hemophilia B classified as severe (plasma factor IX activity of <1%) or moderately severe (plasma factor IX activity of 1 to 2 percent) with a severe bleeding phenotype.” The participants “received continuous factor IX prophylactic therapy” during a six-month lead-in period in which all their bleeding events were tracked and documented. They were infused with a single dose of the gene therapy (2×10^{13} gc per kilogram) then “followed for 18 months after treatment for evaluation of efficacy and safety; they then entered a follow-up phase that extends through 5 years after dosing.” The authors explained that the study’s primary endpoint was “the annualized bleeding rate (based on all bleeding episodes), evaluated in a noninferiority analysis comparing the rate during the 52 weeks after stable factor IX expression (defined uniformly as months 7 through 18 after treatment) with the rate during the lead-in period.” They reported a “decrease” in annualized bleeding rate for all bleeding episodes following the gene therapy infusion “from .19 (95 percent confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95 percent CI, 0.81 to 2.82) in the post-treatment period. The observed annualized bleeding rate ratio for the post-treatment period as compared with the lead-in period was 0.36 (95 percent Wald CI, 0.20 to 0.64; two-sided $P < 0.001$).” They also noted that the “annualized bleeding rate for factor IX–treated bleeding episodes also decreased after treatment (annualized bleeding rate ratio, 0.23; 95 percent Wald CI, 0.12 to 0.46).” The researchers stated each of the 54 participants in the study “had adverse events that occurred or worsened during or after treatment (465 adverse events in total; 364 mild, 87 moderate, and 14 severe).” They concluded that the gene therapy “had a favorable safety and efficacy profile in men with severe or moderately severe hemophilia B [and] was superior to factor IX prophylaxis in terms of the annualized bleeding rate and was associated with sustained increased factor IX activity to the mild to near-normal range [suggesting] that gene therapy may reduce the burden of care and improve quality of life in patients with hemophilia B.”

Citation: Pipe, S., Leebeek, F., Recht, M. *et al.* “[Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.](#)” *NEJM*. 2023.

INFECTIOUS DISEASES UPDATE

SARS-CoV-2

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota [unveiled](#) the Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR). The goal of the [CVR](#) is to “accelerate the development of durable, broadly protective coronavirus vaccines that:

- [r]educe severe illness and death (and potentially prevent infection) due to current and future human coronaviruses, both those known to infect humans and viruses at risk of spilling over from animals to humans in the future;
- [m]itigate the impact of future coronavirus epidemics worldwide;
- [a]re suitable for use in all regions of the globe, including remote areas and low- and middle-income countries.”

The CVR is “organized” into five topic areas: virology applicable to vaccine R&D, immunology and immune correlates of protection, vaccinology, animal and human infection models for coronavirus vaccine research, policy, and financing. An executive summary of the CVR is [available](#).

(Source: CIDRAP [News Release](#), 2/21/23)

(continued on page 5)



INFECTIOUS DISEASES UPDATE (continued from page 4)

Human Immunodeficiency Virus (HIV)

A brief communication [published](#) in *Nature* reported that a 53-year-old German man has been “cured” of HIV following hematopoietic stem cell transplantation (HSCT). According to the researchers, the individual “discontinued antiretroviral therapy (ART) 69 months after HSCT in November 2018, after careful consideration, and no antiretroviral agents were detected in four plasma samples collected after analytical treatment interruption (ATI). On cessation of ART, the patient remained without any clinical or laboratory signs of an acute retroviral syndrome. No rebound of plasma HIV-1 RNA occurred during ATI after 48 months in the absence of ART.” The researchers concluded that “[e]xpansion of [their] approach to introduce the CCR5Δ32 mutation into wild-type stem cell grafts using gene therapy in combination with new reservoir reduction strategies may hold the promise of an HIV-1 cure outside of life-threatening hematological malignancies. This [report] provides detailed information on the virological and immunological signature before and after ATI and generates valuable insights that will hopefully guide future cure strategies.”

Citation: Jensen, B.-E., Knops, E., Cords, L., *et al.* “[In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.](#)” *Nature*. 2023.



Upcoming ABC Webinars – Don't Miss Out!

- **ABC Human Resources Forum Call** – February 27 from 2-3 PM EST. More information available in [MCN 23-014](#) including a link to join the call.
- **ABC Scientific, Medical, and Technical Committee Journal Club Webinar** – March 29 from 3-4 PM EDT. More information coming soon.





PEOPLE



[Jasmine M. Johnson](#) has been named area vice president and Director of Donor Services for Versiti Wisconsin. According to a Versiti news release, her “top priority will be to lead the donor services team in its pursuit of meeting the demand of blood products needed to serve patients, [while overseeing] the team leading Versiti’s ThriveOn King collaboration, a new community resource and permanent blood donation center on Milwaukee’s North Side. Scheduled to open in 2024, the nearly 3,500 square-foot facility will serve as a community hub for Versiti, focused on providing resources to address healthcare

disparities in Milwaukee neighborhoods through training, employment, education, and blood donation.” Ms. Johnson has previously served as the vice president of Sales at Milwaukee’s iHeartMedia Markets Group. She “holds a M.S. degree in Management from Cardinal Stritch University and a B.S. degree in Business Management from the University of Wisconsin-Parkside.”

(Source: Versiti Blood Center of Wisconsin [News Release](#), 2/24/23)

[Jo Farrar, PhD, CB, OBE](#) has been appointed as the next Chief Executive of NHS Blood and Transplant (NHSBT). According to a news release from NHSBT, Dr. Farrar will assume her new role on June 1st. She is an experienced public servant and executive who has held roles in local government, “working with a number of local authorities in [the United Kingdom], culminating in becoming the CEO of two councils – firstly Bridgend in Wales and secondly Bath and North East Somerset.” Dr. Farrar has also served as the “chief Executive HM Prison and Probation Service [where she was] responsible for delivering prison, probation and youth custody services in England and Wales before becoming the Second Permanent Secretary at the Ministry of Justice in March 2021.”



(Source: NHSBT [News Release](#), 2/8/23) ◆

MEMBER NEWS

Research at **Stanford Blood Center** was recently [published](#) in *Cancer Cell*. A team led by Stanford Blood Center Medical Director and Professor of Pathology and Medicine at Stanford University School of Medicine Edgar Engleman, MD, PhD has been working for decades to understand how the immune system responds to cancer. Elevated levels of immune cells, called neutrophils, often suppress the immune system’s response to cancer; but for the first time, the study found that when activated, they eliminate several types of tumors in laboratory mice. Dr. Engleman’s research highlighted how neutrophils can be activated to kill cancers *in vitro* using the same method. He and his team are hopeful that this approach will be used clinically in the near future. He and Ian Linde, PhD, first author of the study, have filed a patent application based on the research.

(Source: Stanford Blood Center Announcement, 2/21/23)

Contributed by Ross Coyle, Public Relations Officer at Stanford Blood Center

(continued on page 7)

MEMBER NEWS (continued from page 6)

The Blood Connection has partnered with Regional Medical Center in Orangeburg, S.C. to meet patients' needs for blood products. Starting in April, Regional Medical Center a non-profit hospital system which provides services to the residents of Orangeburg, Calhoun, Bamberg, and Barnwell counties, and had previously operated its own blood bank and collection efforts, will now use The Blood Connection's services. As part of this partnership, TBC will manage all blood collection operations in the area. "We are excited to partner with Regional Medical Center to continue the strong legacy of blood services in this community," said Delisa English, president and chief executive officer of The Blood Connection, in the announcement. "Regional Medical Center and The Blood Connection have very similar missions, and we believe that this partnership will be a tremendous, long-term asset for RMC patients and this community."

(Source: The Blood Connection Announcement, 2/22/23)

Contributed by Katie Smithson, Partnerships and Media Supervisor at The Blood Connection 💧

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2023

Feb. 27. **ABC Human Resources Forum Call.** Additional information including a link to join the call available [here](#).

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** [Registration](#) is open. Additional information is available [here](#).

Mar. 29. **ABC Scientific, Medical, and Technical Committee Journal Club Webinar.** More information coming soon.

April 24-28. **ABC Blood Advocacy Week.** More information available [here](#).

April 26. **ABC Day on Capitol Hill.** [Registration](#) is open. More information available [here](#).

April 27. **U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) Public Listening Meeting: Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products (Virtual).** More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

Aug. 1-3. **ABC Medical Directors Workshop and Summer Summit, St. Louis, Mo.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧



CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Executive Director, Operations – Eastern Wisconsin/UP Michigan. The Community Blood Center (CBC) (a division of Midwest Blood Centers, Inc. (MBC)) is looking to hire an Executive Director, Operations – Eastern Wisconsin/UP Michigan. Responsible for achieving the organizational objectives of the business unit within (CBC). This includes collaborating with executive-level management in the development, oversight and expansion of blood recruitment, collections, manufacturing and hospital services activities. Accountable for ensuring operations are compliant with all applicable regulations, standards and organizational policies. Create an engaged, collaborative and productive culture while ensuring blood donors and blood drive sponsors receive exceptional service. At CBC, we lead our teams while keeping our mission, vision, and values at the forefront of all that we do. As a leader, you will inspire, train and collaborate with those in your department accordingly in addition to focusing on the organization's strategic goals. Essential duties include develop, implement and monitor day-to-day operational systems and processes in the areas of field donor recruitment, blood donor collections, manufacturing and hospital services. Participate in strategic and annual planning of the organization. Provide the processes, infrastructure, staff and training to ensure exceptional, skillful and knowledgeable services are provided. Effectively initiates, implements and manages change within the organization. Read full job description and apply: <https://www.communityblood.org/current-openings/executive-director-operations/>.

Medical Director (Oklahoma City, OK). The Our Blood Institute, a large, successful blood center servicing Oklahoma, Arkansas, Texas and beyond, seeks qualified candidates for the position of **Medical Director**. Successful applicants must be **board-certified AP/CP or CP-only pathologists with board certification/eligibility** in Blood Banking/Transfusion Medicine. The Medical Director will work with the Chief Medical Officer (CMO) and other Medical Directors to direct and supervise key staff with the obligation to ensure that the quality of all products manufactured is in compliance with all regulatory requirements. In conjunction with the CMO and other staff, the Medical Director exercises control over the Institute's operations regarding all matters relating to compliance. The FACT Facility Medical Director shall have postgraduate training in cellular therapy practices and two years of practical experience in product collection, preparation, and clinical use of cell therapy products. If you are a doctor looking both to deliver excellence patient and donor care via multifaceted transfusion medicine organization and to reimagine the

mission of blood banking in meeting community needs for connectivity, compassion, altruism and healing, this could be the perfect job for you. Salary Range: Competitive salary with excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. **How to apply:** <http://obi.org/careers>

Territory Sales Consultant (Tulsa, Oklahoma). Territory Sales Consultants must develop new partnerships with targeted decision makers in community organizations, educational & religious institutions, and businesses to gain support in meeting the needs for volunteer blood donors. Responsibilities include organizing & promoting blood donation events; assessing, developing, and implementing strategic/tactical plans to achieve recruitment objective/goals. She/he is expected to develop a customer-focused culture that will result in successful community partnerships and donation awareness. Identify opportunities for growth within current group base and facilitate a plan to achieve growth percentage for total unit collection within territory. Book recurring blood drives for the following year. Develop and maintain relationships with key accounts. Give presentations to promote blood collection. Identify and provide feedback on issues regarding customer needs/requirements, customer issues/concerns and satisfaction, competitor activities/strategies, etc. Interact effectively and professionally with team members and all internal/external contacts. Qualifications: Associate/Bachelor's degree preferred, one to three years sales related experience, public speaking/presentation experience preferred, excellent communication skills, and valid driver's license with access to vehicle. Salary Range: Competitive salary, commission plan, and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. How to apply: <http://obi.org/careers/>.

Chief Executive Officer (Flowood, MS). Mississippi Blood Services makes a difference in people's lives every day. With the support of the community and voluntary blood donors, we have been serving the needs of hospital patients since 1979. To help us meet our mission, as part of a planned retirement, we are looking for a new Chief Executive Officer with the necessary expertise to direct all functions of the corporation in accordance with Board directives and regulatory guidelines in order to attain strategic objectives. The CEO will provide leadership to provide exceptional service and products to hospitals giving maximum consideration to the safety and efficiency

(continued on page 9)



POSITIONS (continued from page 8)

of those products and services, direct overall operation of the corporation, ensure implementation of established policies and acts as liaison with the Board of Directors, and maintain positive relationships with the business and medical community, civic groups, and other blood banking organizations. Education and/or Experience: Bachelor's degree (B.A.) or higher from a four-year college or university; 10 years of related experience preferably with either large nonprofits or blood services/products organizations; or equivalent combination of education and experience. Click [here](#) to view the full job description. Mississippi Blood Services is an equal opportunity employer and makes employment decisions without regard to race, color, sex, religion, national origin, age, disability, veteran status, genetic information, sexual orientation or gender identity. Please submit cover letter, resume and salary requirements to Kiffany Lee, Director of Human Resources klee@msblood.com.



Director, Scientific and Technical Operations. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a **Director, Scientific and Technical Operations**. The position will lead the association's evaluation and response to new Scientific, Medical, Technical Operations, Quality and Regulatory (SMTQR) developments, including the development of programs and resources. The position will report directly to the Senior Director, Federal Government Affairs, providing strategic guidance on emerging trends in the blood community and transfusion medicine to help shape strategies that leverage the ABC membership to drive ABC's advocacy work. Primary Responsibilities: Direct the development of programs and resources that support member activities in SMTQR and operational areas, including Journal Club, *Blood Bulletin*, workshops, and webinars. Convene ABC members to share best practices and collaborate in advancing ABC's advocacy agenda and hot topics of importance to blood centers. Assist in the analysis of new standards, guidelines, and regulations. Provide consultative services to ABC member requests for information and assistance in SMTQR areas. Serve as the primary staff liaison to the ABC Quality Committee and subcommittees, and Quality and HR Forums. Oversee ABC's research, benchmarking, and survey programs, including the use of the data to improve member blood center operations and the identification of best practices. Educational Requirements: Bachelor's required. Experience, Knowledge, Skills, and Abilities: A minimum of five years of experience in blood banking, with emphasis in any of the areas of scientific, medical, quality, technical operations, and/or regulatory affairs. Blood center operational experience a plus. Possesses demonstrated analytic and communication skills. Strong customer service orientation and ability to navigate and respond to sensitive/difficult situations. Self-motivated, flexible, creative, innovative, and goal oriented. This position is virtual. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to careers@americasblood.org. 💧